Purpose: Familial hyperaldosteronism type 1 (FH-1) is a rare autosomal dominant form of primary aldosteronism, which features a marked phenotypic heterogeneity, ranging from mild to severe forms of arterial hypertension that can be complicated by stroke and cardiovascular events at a young age. As affected patients usually reach the fertile age, transmission of the disease to offspring is common. Notwithstanding this, reports of FH-1 in pregnancy are limited and there is a lack of treatment guidelines.
Methods And Results: We searched the PubMed and EuropePMC databases with a PICO strategy to retrieve available information on management of FH-1 patients during pregnancy. We could identify seven relevant articles, which are herein reviewed.
Conclusion: Based on available information on pathophysiology and treatment of FH-1 in pregnancy, recommendations for the rational management of FH-1 in pregnancy are provided.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440273 | PMC |
| http://dx.doi.org/10.1007/s12020-021-02763-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A systematic review of pathophysiology and management of familial hyperaldosteronism type 1 in pregnancy.
Endocrine
October 2021
Hypertension and Emergency Unit, Department of Medicine - DIMED, University of Padua, Padova, Italy.
Purpose: Familial hyperaldosteronism type 1 (FH-1) is a rare autosomal dominant form of primary aldosteronism, which features a marked phenotypic heterogeneity, ranging from mild to severe forms of arterial hypertension that can be complicated by stroke and cardiovascular events at a young age. As affected patients usually reach the fertile age, transmission of the disease to offspring is common. Notwithstanding this, reports of FH-1 in pregnancy are limited and there is a lack of treatment guidelines.
View Article and Find Full Text PDFFamilial hyperaldosteronism type 1 and pregnancy: successful treatment with low dose dexamethasone.
Blood Press
April 2021
Hypertension and Emergency Unit, Department of Medicine - DIMED, University of Padua, Padova, Italy.
Purpose: Familial hyperaldosteronism type 1 (FH-1) is an autosomal dominant form of primary aldosteronism (PA), featuring a marked phenotypic heterogeneity, ranging from mild forms of PA and arterial hypertension (HT) to severe forms complicated by stroke at a young age. Affected patients usually reach the fertile age; hence, transmission of the disease to offspring is common. Notwithstanding this, only anecdotal reports of FH-1 in pregnancy exist and recommendations for treatment remain vague.
View Article and Find Full Text PDFHuman pregnancy levels of estrogen and progesterone contribute to humoral immunity by activating T /B cell axis.
Eur J Immunol
January 2021
Department of Microbiology and Parasitology, Federal University of the State of Rio de Janeiro, Rio de Janeiro, Brazil.
Circulating T (cT ) cells express CXCR5, PD-1, and, when activated, ICOS, and release IL-21. According to the production of IFN-γ, IL-4, and IL-17 and expression of FoxP3, these cells are also classified as cT 1, cT 2, cT 17, and cT cells, respectively. This CD4 T-cell subset is pivotal to efficient humoral immunity, and pregnancy appears to favor IgG production.
View Article and Find Full Text PDFDifferent effects of progesterone and estradiol on chimeric and wild type aldosterone synthase in vitro.
Reprod Biol Endocrinol
August 2013
Molecular Endocrinology Laboratory, Department of Endocrinology, School of Medicine, Pontificia Universidad Catolica de Chile, Lira 85, 5th Floor, Santiago, Chile.
Background: Familial hyperaldosteronism type I (FH-I) is caused by the unequal recombination between the 11beta-hydroxylase (CYP11B1) and aldosterone synthase (CYP11B2) genes, resulting in the generation of a CYP11B1/B2 chimeric gene and abnormal adrenal aldosterone production. Affected patients usually show severe hypertension and an elevated frequency of stroke at a young age. Aldosterone levels rise during pregnancy, yet in pregnant women with FH-1, their hypertensive condition either remains unchanged or may even improve.
View Article and Find Full Text PDFGestational age determination and prevention of HIV perinatal transmission.
Int J Gynaecol Obstet
February 2006
Institut de Recherche pour le Développement (IRD), Chiang Mai, Thailand.
Objective: To compare different methods of gestational age (GA) measurement for ensuring effective zidovudine (ZDV) prophylaxis to prevent mother-to-child transmission of HIV.
Methods: For 1398 HIV-infected women enrolled in a perinatal prevention trial, gestation durations were calculated based on GA estimated using ultrasound (US), date of last menstruation period (LMP), first fundal height (FH(1)), and a specific algorithm was developed to provide a "reference" GA. The performance of each GA estimate was evaluated by the percentage of women who would have received > or =8 weeks ZDV, if prophylaxis was initiated at 28 weeks.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!